Malta - English - Medicines Authority

accord healthcare limited - topotecan - concentrate for solution for infusion - topotecan 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - topotecan - concentrate for solution for infusion - topotecan 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - topotecan - powder for concentrate for solution for infusion - topotecan 4 mg - antineoplastic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - topotecan (topotecan hydrochloride) - powder for solution - 1mg - topotecan (topotecan hydrochloride) 1mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - topotecan (as hydrochloride) - pdr/conc/soln for infus - 4 milligram

Canada - English - Health Canada

pharmascience inc - topotecan (topotecan hydrochloride) - powder for solution - 1mg - topotecan (topotecan hydrochloride) 1mg - antineoplastic agents

Canada - English - Health Canada

pharmascience inc - topotecan (topotecan hydrochloride) - powder for solution - 4mg - topotecan (topotecan hydrochloride) 4mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 4.346 mg (equivalent: topotecan, qty 4 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; tartaric acid - topotecan intas is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan intas is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.